Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Mol Cancer Ther. 2020 Dec 8;20(2):274–283. doi: 10.1158/1535-7163.MCT-20-0567

Figure 6. Leflunomide treatment attenuated lung metastasis in a WRJ388-based subcutaneous model.

Figure 6.

(A) Hematoxylin and eosin (H&E) and TTF1 immunohistochemically stained lung tissue sections from a mouse with subcutaneously implanted WRJ388. (B) Tumor volume analysis with (red) or without (blue) 35mg/kg/day leflunomide treatment. (C) Animal weight analysis during the same period. (D) Photos of isolated subcutaneous WRJ388 tumors on Day 24. (E) Tumor weight comparison in both groups. (F) BLI signal comparison in the lung in control and leflunomide-treated groups. (G) Type of metastasis in the lung by pathological analysis.